CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 792,065	$ 535,203
Marketable securities	586,879	503,481
Accounts receivable - trade, net	1,532,693	1,343,368
Accounts Receivable from Sanofi	217,478	92,989
Accounts receivable from Bayer	221,278	175,263
Inventories	641,588	399,356
Prepaid expenses and other current assets	143,761	130,528
Total current assets	4,135,742	3,180,188
Marketable securities	1,327,303	864,260
Property, Plant, and Equipment, Net	2,274,529	2,083,421
Deferred tax assets	927,023	825,303
Other assets	36,618	20,294
Total assets	8,701,215	6,973,466
Current liabilities:
Accounts payable and accrued expenses	818,426	879,096
Capital and facility lease obligations, current	0	129,557
Deferred revenue from Sanofi, current portion	187,036	115,267
Deferred Revenue, Current	132,832	116,397
Other current liabilities	334	1,178
Total current liabilities	1,138,628	1,241,495
Capital and facility lease obligations	702,317	351,569
Deferred revenue from Sanofi	408,786	503,474
Deferred Revenue, Noncurrent	274,666	327,298
Other long-term liabilities	125,225	100,385
Total liabilities	2,649,622	2,524,221
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	3,570,673	3,029,993
Retained earnings	2,773,214	1,748,222
Accumulated other comprehensive income (loss)	23,835	(12,840)
Treasury stock	(316,240)	(316,240)
Total stockholders' equity	6,051,593	4,449,245
Total liabilities and stockholders' equity	8,701,215	6,973,466
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 109	$ 108